{"entity":{"id":"paper-tebentafusp-melanoma-cancers-basel-2019","kind":"paper","name":"Tebentafusp: T Cell Redirection for the Treatment of Metastatic Uveal Melanoma","aka":[],"tldr":"Review on Tebentafusp in Melanoma, in Cancers (2019), one of the most cited Europe PMC records with Tebentafusp in its title.","summary":"Metastatic disease from uveal melanoma occurs in almost 50% of patients suffering from this ocular tumour, with median survival from development of symptoms being around 1 year. In contrast to cutaneous melanoma, kinase inhibitors and immune checkpoint inhibitors are usually ineffective in patients with metastatic uveal melanoma. Tebentafusp is a novel form of immunotherapy based on the immune-mobilising monoclonal T cell receptor against cancer (ImmTAC) platform, which comprises a soluble T cell receptor that is fused to an anti-CD3 single-chain variable fragment. The T cell receptor domain of tebentafusp targets cells present a human leukocyte antigen-A*02:01 complexed with a peptide derived from the melanoma-associated antigen gp100, which is expressed strongly by melanoma cells, weakly by normal melanocytes and minimally by other tissues. The anti-CD3 domain recruits CD3+ T cells (and, indirectly, other immune cells), redirecting these to the melanoma cells. The most common adverse events with tebentafusp are manageable and usually transient. Early survival data in patients with metastatic uveal melanoma are promising when considered alongside historical data. Based on these encouraging results, a randomised study comparing tebentafusp to investigator's choice of therapy in metastatic uveal melanoma is ongoing.\n\nIndexed on Europe PMC as PubMed record 31336704 (DOI 10.3390/cancers11070971). Its title names Tebentafusp and its text names Melanoma; PubMed types it as a review (review-article, Review). It was matched automatically to the idea \"TCR therapeutics for non-HLA-A*02 patients\" and no figure has been checked by an editor.","asOf":"2026-09-22","links":[{"label":"Cancers (Basel) 2019","url":"https://doi.org/10.3390/cancers11070971"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/31336704/"},{"label":"Europe PMC","url":"https://europepmc.org/article/MED/31336704"}],"tags":["europepmc-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancers-mdpi"],"dependsOn":[],"notes":[],"journal":"Cancers","year":2019,"doi":"10.3390/cancers11070971","pmid":"31336704","authors":"Damato BE, Dukes J, Goodall H, et al.","paperType":"review","findings":[],"whatItMeans":"One of the most cited reviews Europe PMC returns for Tebentafusp in Melanoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.","caveats":["Matched by Tebentafusp in the title and Melanoma in the title or abstract of the Europe PMC record; the summary reproduces the record's abstract and no figure has been verified against the full paper.","A review summarises other studies; the primary reports it cites are the evidence."]},"route":"/key-papers/paper-tebentafusp-melanoma-cancers-basel-2019/","neighbours":{"journal":[{"id":"cancers-mdpi","kind":"journal","name":"Cancers","route":"/journals/cancers-mdpi/"}],"idea":[{"id":"idea-prame-tcr-beyond-a02","kind":"idea","name":"TCR therapeutics for non-HLA-A*02 patients","route":"/ideas/idea-prame-tcr-beyond-a02/"}]}}